Kite Pharma a Rare Opportunity for Investors using Artificial Intelligence

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Share on pinterest
Kite Pharma a Rare Opportunity for Investors using Artificial Intelligence. Kite Pharma is currently one of our major investments in the biotech sector. We foresee a bright future for this company.

Kite Pharma a Rare Opportunity for Investors using Artificial Intelligence

Kite Pharmaceuticals is currently one of our major investments in the biotech sector. We foresee a bright future for this company.

Triple digit ROI investing in companies no one believes in or knows about is common. Take the example of Hertz (HTZ), a company very few believed in just a few weeks ago, but one of the best investments for 2017. Today any Hertz investor has 100% ROI guaranteed!

Autonomous Trading has a Strong Buy rating on Kite Pharma (KITE) shares which are currently soaring to new all0time highs to $128

KITE PHARMA NEWS: Beating Warren Buffett Daily Trading BlueBird Bio and Kite Pharma $BLUE $KITE

We have a Strong Buy rating on Kite Pharma since $45. You will not see these prices again. Invest for the long haul as we have been doing for thirty years.

Vieira

Kite Pharma, Inc. (KITE), a leading cell therapy company, today reported second quarter 2017 financial results and provided a corporate update for the period ended June 30, 2017.

“We’ve continued to make significant progress on key clinical and commercial milestones in the last six months alone,” said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. “With the anticipated events on the horizon for the remainder of 2017, the potential for CAR-T to become one of the most powerful anti-cancer agents for certain patients may finally be realized.”

Second Quarter 2017 Financial Results

  • Revenue was $10.1 million for the second quarter of 2017.
  • Research and development expenses were $70.9 million for the second quarter of 2017, including $13.1 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $41.1 million for the second quarter of 2017, including $12.1 million of non-cash stock-based compensation expense.
  • Net loss was $109.8 million, or $1.94 per share, for the second quarter of 2017.
  • Non-GAAP net loss for the second quarter of 2017 was $84.7 million, or $1.50 per share, excluding non-cash stock-based compensation expense of $25.2 million.
  • As of June 30, 2017, Kite had $781.1 million in cash, cash equivalents, and marketable securities.
Louis Rosenthal

Louis Rosenthal

I am the author of the famous article Short GoPro stock is worth $1 Billion Profit - hopefully you can find in my ideas and articles useful information. I started in the markets investing in Intuitive Surgical many years ago by following Vieira's guidance later on becoming a contributor 

About Us

Intuitive AI Code is the leader in artificially intelligent algorithms with applications in numerous industries such as intelligence, finance, defence, and trading. 

We started in 1989 in tribute to the Russian mathematician Grigori Perelman, Fields medal. Compare our 30 years’ historical record with other markets participants.

Recent Articles

Uncanny AI Forecasts
Beyond Meat $46 to $202

Follow Us

Sign up for our Newsletter

We do not sell mailing lists. We don’t use Ads. Our research and analysis blows the competition out of the water.



Scroll to Top